Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helle Linnebjerg

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
International Journal of Clinical Pharmacology and Therapeutics|June 3, 2014
Modeling and simulations to confirm a controlled hypoglycemic stress test in healthy subjects is not associated with clinically significant QT prolongationsLai San Tham, Crystal Mei Fen Zhao, Fanni Natanegara, et al.
Diabetes, Obesity & Metabolism|November 27, 2016
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetesNiels Porksen, Helle Linnebjerg, Parag Garhyan, et al.
Journal of the American College of Cardiology|March 30, 2025
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human StudiesKausik K Ray, Helle Linnebjerg, Laura F Michael, et al.
Diabetes Care|October 14, 2011
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsAmparo de la Peña, Matthew Riddle, Linda A Morrow, et al.
Journal of Diabetes Science and Technology|November 27, 2020
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin RequirementsXiaosu Ma, Charles T Benson, Randy Prescilla, et al.
Journal of Clinical Pharmacology|December 3, 2008
Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitusPrajakti A Kothare, Helle Linnebjerg, Yoshitaka Isaka, et al.
American Heart Journal|June 22, 2015
Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research ConsortiumSimon Heller, Börje Darpö, Malcolm I Mitchell, et al.
Diabetes Care|June 21, 2014
Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjectsRobert R Henry, Sunder Mudaliar, Theodore P Ciaraldi, et al.
Nucleic Acids Research|September 29, 2025
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendationsJesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
International Journal of Clinical Pharmacology and Therapeutics|June 3, 2014
Modeling and simulations to confirm a controlled hypoglycemic stress test in healthy subjects is not associated with clinically significant QT prolongationsLai San Tham, Crystal Mei Fen Zhao, Fanni Natanegara, et al.
Diabetes, Obesity & Metabolism|November 27, 2016
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetesNiels Porksen, Helle Linnebjerg, Parag Garhyan, et al.
Journal of the American College of Cardiology|March 30, 2025
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human StudiesKausik K Ray, Helle Linnebjerg, Laura F Michael, et al.
Diabetes Care|October 14, 2011
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsAmparo de la Peña, Matthew Riddle, Linda A Morrow, et al.
Journal of Diabetes Science and Technology|November 27, 2020
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin RequirementsXiaosu Ma, Charles T Benson, Randy Prescilla, et al.
Journal of Clinical Pharmacology|December 3, 2008
Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitusPrajakti A Kothare, Helle Linnebjerg, Yoshitaka Isaka, et al.
American Heart Journal|June 22, 2015
Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research ConsortiumSimon Heller, Börje Darpö, Malcolm I Mitchell, et al.
Diabetes Care|June 21, 2014
Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjectsRobert R Henry, Sunder Mudaliar, Theodore P Ciaraldi, et al.
Nucleic Acids Research|September 29, 2025
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendationsJesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, et al.
Pageof 4